Strangely, Brexit and then the Covid-19 pandemic have combined to create ideal conditions for the UK to potentially become a leader in psychedelics research.
From Brexit came conditions for a new “fast-track” medicinal approval regulatory pathway. This combined with increased emphasis on life sciences as well as streamlined research and risk-assessment changes brought about by Covid-19 to create an ideal scenario for psychedelics start-ups to take off. However, before these new enterprises can fully get going, further conditions must still be met, such as acceptance by UK medical professionals of treatments using psychedelics.